222 related articles for article (PubMed ID: 35334495)
21. Quantification and Characterization of CTCs and Clusters in Pancreatic Cancer by Means of the Hough Transform Algorithm.
Calero-Castro FJ; Pereira S; Laga I; Villanueva P; Suárez-Artacho G; Cepeda-Franco C; de la Cruz-Ojeda P; Navarro-Villarán E; Dios-Barbeito S; Serrano MJ; Fresno C; Padillo-Ruiz J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901704
[TBL] [Abstract][Full Text] [Related]
22. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer.
Wei T; Zhang X; Zhang Q; Yang J; Chen Q; Wang J; Li X; Chen J; Ma T; Li G; Gao S; Lou J; Que R; Wang Y; Dang X; Zheng L; Liang T; Bai X
Cancer Lett; 2019 Jun; 452():237-243. PubMed ID: 30905814
[TBL] [Abstract][Full Text] [Related]
23. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal Adenocarcinoma.
Javed AA; Floortje van Oosten A; Habib JR; Hasanain A; Kinny-Köster B; Gemenetzis G; Groot VP; Ding D; Cameron JL; Lafaro KJ; Burns WR; Burkhart RA; Yu J; He J; Wolfgang CL
Ann Surg; 2023 Jun; 277(6):866-872. PubMed ID: 36111839
[TBL] [Abstract][Full Text] [Related]
24. Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH.
Li Y; Ma G; Zhao P; Fu R; Gao L; Jiang X; Hu P; Ren T; Wu Y; Wang Z; Cui Z; Yang D
Clin Chim Acta; 2018 Oct; 485():95-102. PubMed ID: 29940145
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of phenotyping and karyotyping of detecting circulating tumor cells in renal cell carcinoma using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH).
Tian D; Zhang M; Zheng G; Zhang Y; Li Y; Lin P; Li H; Jiao W; Niu H
Int Urol Nephrol; 2020 Dec; 52(12):2281-2287. PubMed ID: 32748196
[TBL] [Abstract][Full Text] [Related]
26. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
27. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
[TBL] [Abstract][Full Text] [Related]
29. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
30. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.
Gu Y; Hua Q; Li Z; Zhang X; Lou C; Zhang Y; Wang W; Cai P; Zhao J
BMC Cancer; 2023 Mar; 23(1):227. PubMed ID: 36899319
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma.
Park Y; Jun HR; Choi HW; Hwang DW; Lee JH; Song KB; Lee W; Kwon J; Ha SH; Jun E; Kim SC
Sci Rep; 2021 Jan; 11(1):1644. PubMed ID: 33462311
[TBL] [Abstract][Full Text] [Related]
33. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma.
White MG; Lee A; Vicente D; Hall C; Kim MP; Katz MHG; Lee JE; Ikoma N; Lucci A; Tzeng CD
Ann Surg Oncol; 2021 Aug; 28(8):4615-4622. PubMed ID: 33415562
[TBL] [Abstract][Full Text] [Related]
34. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
[TBL] [Abstract][Full Text] [Related]
35. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
36. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.
Khoja L; Backen A; Sloane R; Menasce L; Ryder D; Krebs M; Board R; Clack G; Hughes A; Blackhall F; Valle JW; Dive C
Br J Cancer; 2012 Jan; 106(3):508-16. PubMed ID: 22187035
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of circulating tumor cells detection in renal cell carcinoma with thrombus: A STROBE-compliant study.
Ge L; Song Y; Yang F; Zhao G; Lu M; Zhang S; Ma L
Medicine (Baltimore); 2020 May; 99(22):e20615. PubMed ID: 32481476
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study.
Gemenetzis G; Groot VP; Yu J; Ding D; Teinor JA; Javed AA; Wood LD; Burkhart RA; Cameron JL; Makary MA; Weiss MJ; He J; Wolfgang CL
Ann Surg; 2018 Sep; 268(3):408-420. PubMed ID: 30080739
[TBL] [Abstract][Full Text] [Related]
39. Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer.
Cheng H; He W; Yang J; Ye Q; Cheng L; Pan Y; Mao L; Chu X; Lu C; Li G; Qiu Y; He J
Cell Prolif; 2020 Sep; 53(9):e12880. PubMed ID: 32707596
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
